Pyridine and pyrazine derivative for the treatment of CF
USRE46757E1 · kind E1 · reissue
1Cited by
104References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2015 |
| Grant date | Mar 20, 2018 |
| Priority date | — |
| Expiry date | Jun 30, 2035 |
Classification
- Technology area (CPC —)General
Abstract
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.